医学
幽门螺杆菌
内科学
需要治疗的数量
胃肠病学
荟萃分析
相对风险
随机对照试验
安慰剂
置信区间
替代医学
病理
作者
Alexander C. Ford,Evangelos Tsipotis,Yuhong Yuan,Grigorios I. Leontiadis,Paul Moayyedi
出处
期刊:Gut
[BMJ]
日期:2022-01-12
卷期号:71 (10): 1967-1975
被引量:75
标识
DOI:10.1136/gutjnl-2021-326583
摘要
OBJECTIVE: . DESIGN: -positive adults with FD. The control arm received antisecretory therapy or prokinetics, with or without placebo antibiotics, or placebo alone. Follow-up was for ≥3 months. We pooled dichotomous data to obtain a relative risk (RR) of symptoms not being cured or symptoms not improving with a 95% CI. We estimated the number needed to treat (NNT). RESULTS: than with unsuccessful eradication (RR=0.65; 95% CI 0.52 to 0.82, NNT=4.5, 95% CI 3 to 9). Adverse events (RR=2.19; 95% 1.10 to 4.37) and adverse events leading to withdrawal (RR=2.60; 95% CI 1.47 to 4.58) were more common with eradication therapy. CONCLUSION: eradication therapy leads to both cure and improvement in FD symptoms, although the benefit is modest.
科研通智能强力驱动
Strongly Powered by AbleSci AI